# STRATA Skin Sciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/STRATA Skin Sciences, Inc.). ## Overview STRATA Skin Sciences, Inc. is a U.S.-based medical technology company focused on dermatology devices and treatment systems. Its portfolio includes excimer laser and lamp platforms used by dermatologists to treat psoriasis, vitiligo, acne, and other skin conditions, with sales and procedures centered in the United States and select international markets. ## Products & services • XTRAC® excimer laser systems for psoriasis and vitiligo • Pharos® excimer laser systems for dermatologic conditions • VTRAC® lamp systems for skin disease treatment • TheraClear® X Acne Therapy System for acne-related conditions • Recurring treatment procedures and device placements - **Dermatology recurring procedures** (72%) — Treatment revenue from XTRAC procedures and TheraClear device placements recognized over usage. - **Dermatology procedures equipment** (28%) — Sales of excimer lasers, lamp systems, accessories, and related equipment to practices. - XTRAC® excimer laser systems for psoriasis and vitiligo - Pharos® excimer laser systems for dermatologic conditions - VTRAC® lamp systems for skin disease treatment - TheraClear® X Acne Therapy System for acne-related conditions - Recurring treatment procedures and device placements ## Customers The company sells primarily to dermatology practices and physicians that treat chronic and recurring skin conditions. Its recurring procedures model also serves offices that place STRATA devices and then generate treatment revenue as patients use the systems. Demand is tied to clinical adoption, reimbursement coverage, and the ability of practices to attract patients needing psoriasis, vitiligo, or acne therapy. - **Dermatology practices** (primary) — Buy XTRAC, Pharos, and VTRAC systems to treat psoriasis, vitiligo, and other skin diseases in-office. - **Recurring procedure offices** (primary) — Place STRATA devices and generate treatment revenue as patients return for repeated sessions. - **Acne treatment providers** (secondary) — Use TheraClear X for acne-related skin conditions and related patient care workflows. - **International dermatology customers** (secondary) — Purchase equipment and procedures outside the U.S. where the company has international exposure. - Dermatologists buying systems for in-office skin treatments - Medical practices using recurring procedure platforms - Physicians treating psoriasis and vitiligo patients - Clinics offering acne therapy with TheraClear X - Customers value reimbursement support and repeatable treatment demand ## Geography STRATA is headquartered in the United States and its reported recurring procedures activity is concentrated there. The company also notes international customer activity, which can affect collections timing and exposure to trade policy, tariffs, and cross-border supply chain costs. Geography matters because the business depends on U.S. reimbursement dynamics while importing components and serving some customers abroad. - United States is the core market for devices and recurring procedures - International customer sales can take longer to collect - Imported components expose the business to tariff and trade policy risk - U.S. reimbursement coverage supports adoption of XTRAC procedures ## Strategy STRATA’s strategy centers on expanding installed base usage, placing devices in dermatology offices, and converting that footprint into recurring treatment revenue. It also emphasizes product development and commercialization across dermatology indications, while managing the economics of device refurbishment and redeployment to support utilization. - **Expand recurring procedure utilization** (short-term) — Recurring treatments create repeat revenue tied to installed devices and patient flow. - **Increase installed base and device placements** (medium-term) — A larger installed base supports future procedure volume and customer retention. - **Optimize device lifecycle economics** (medium-term) — Refurbishing and redeploying units can lower capital needs versus building new systems. - Grow recurring treatment revenue through higher procedure utilization - Place more devices in dermatologists' offices - Support adoption of XTRAC and TheraClear platforms - Refurbish and redeploy recalled or underperforming units - Manage trade and sourcing exposure tied to imported components ## Risks The business is exposed to reimbursement, adoption, and utilization risk because a meaningful share of revenue depends on repeated dermatology procedures. It also faces tariff, import, and supply-chain risk because products and components may be sourced across borders, while accounting estimates such as revenue deferrals, goodwill, and sales tax liabilities can materially affect reported results. - **Tariffs and trade restrictions** [high] — Imported products or components may become more expensive and less competitive. - **Reimbursement and utilization dependence** [high] — Recurring procedure revenue depends on insurance coverage and patient treatment volume. - **International collection timing** [medium] — The company noted longer payment cycles from international customers. - **Goodwill and intangible impairment** [high] — Device and reporting-unit values depend on future cash flow assumptions. - Tariffs can raise component costs and reduce demand - Procedure revenue depends on patient volume and reimbursement - International customers may pay more slowly - Goodwill and intangibles can be impaired if performance weakens - Sales tax and revenue deferral estimates can change reported results ## Accounting Revenue recognition is central because recurring procedure revenue is recognized over the estimated usage period of treatments, while equipment sales follow different timing. The company also relies on estimates for deferred revenue, contingent consideration, goodwill impairment, and sales tax liabilities, all of which can materially change quarterly results when assumptions are revised. - **Revenue recognition for recurring procedures** — Can shift revenue between periods - **Deferred revenue on domestic placements** — Affects reported revenue and contract liabilities - **Goodwill impairment** — Can create non-cash charges if expected cash flows weaken - **Sales tax liability estimates** — Can alter liabilities, operating expense, and goodwill carrying value - Recurring procedure revenue is recognized over treatment usage - Device placements create deferred revenue balances - Goodwill impairment depends on reporting-unit cash flow estimates - Contingent consideration affects purchase accounting and expense - Sales tax accrual estimates can change liabilities and expense --- *Last updated: 2026-04-29T04:56:50.258030+00:00*